LEAC-102 for Advanced Colorectal Cancer
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer
Advanced Colorectal Cancer
DRUG: LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
Maximum tolerated dose, First two cycles of FOLFOX + Bevacizumab/Cetuximab for advanced Colorectal Cancer (cycle length = 2 weeks), Week 4
Incidence of adverse events (AEs), Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Incidence of serious adverse events (SAEs), Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Response rate, Week 24|Progression free survival, Week 24|Overall survival, Week 24|Incidences of myelosuppression, Weeks Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Change in white blood cells (WBCs) level at all post-treatment visits compared to baseline, Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Change in platelet level at all post-treatment visits compared to baseline, Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Change in hemoglobin level at all post-treatment visits compared to baseline, Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Change in serum inflammatory cytokines level at all post-treatment visits compared to baseline, Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Change in serum c-reactive protein level at all post-treatment visits compared to baseline, Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24|Changes in global health/QoL standardized score at post-treatment visits compared to baseline, Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer